Drugs and Devices for Weight Management
August 4, 2025 (Issue: 1734)
Overweight is generally defined as a body mass
index (BMI) between 25 and 29.9 kg/m2 in adults. A
BMI ≥30 is considered obese (criteria differ slightly in
Asian patients). In patients with an elevated BMI, a
5-10% reduction in weight has been...more
- J-H Haam et al. Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity. J Obes Metab Syndr 2023; 32:121. doi:10.7570/jomes23031
- DH Ryan and SR Yockey. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep 2017; 6:187. doi:10.1007/s13679-017-0262-y
- O Gilbert et al. 2025 concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2025 June 20 (epub). doi:10.1016/j.jacc.2025.05.024
- E Grunvald et al. AGA clinical practice guidelines on pharmacological interventions for adults with obesity. Gastroenterology 2022; 163:1198. doi:10.1053/j.gastro.2022.08.045
- Tirzepatide (Zepbound) for chronic weight management. Med Lett Drugs Ther 2023; 65:205.
- Semaglutide (Wegovy) for weight loss. Med Lett Drugs Ther 2021; 63:106.
- Liraglutide (Saxenda) for weight loss. Med Lett Drugs Ther 2015; 57:89.
- LJ Aronne et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025; 393:26. doi:10.1056/nejmoa2416394
- WT Garvey et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023; 402:613. doi:10.1016/s0140- 6736(23)01200-x
- AM Jastreboff et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 2025; 392:958. doi:10.1056/nejmoa2410819
- Drugs for chronic heart failure. Med Lett Drugs Ther 2025; 67:81.
- M Packer et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025; 392:427. doi:10.1056/nejmoa2410027
- Tirzepatide (Zepbound) for obstructive sleep apnea. Med Lett Drugs Ther 2025; 67:29.
- A Malhotra et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024; 391:1193. doi:10.1056/nejmoa2404881
- JPH Wilding et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384:989. doi:10.1056/nejmoa2032183
- TA Wadden et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021; 325:1403. doi:10.1001/jama.2021.1831
- M Davies et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021; 397:971. doi:10.1016/s0140- 6736(21)00213-0
- DM Rubino et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022; 327:138. doi:10.1001/jama.2021.23619
- AM Lincoff et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023; 389:2221. doi:10.1056/nejmoa2307563
- A renal indication for semaglutide (Ozempic). Med Lett Drugs Ther 2025; 67:38.
- T Kanie et al. Dipeptidyl peptidase-4 inhibitors, glucagonlike peptide 1 receptor agonists and sodium-glucose cotransporter- 2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev 2021; 10:CD013650. doi:10.1002/14651858.cd013650.pub2
- BM McGowan et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol 2024; 12:631. doi:10.1016/s2213-8587(24)00182-7
- MN Kosiborod et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023; 389:1069. doi:10.1056/nejmoa2306963
- MN Kosiborod et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024; 390:1394. doi:10.1056/nejmoa2313917
- WT Garvey et al. Efficacy and safety of oral semaglutide 25 mg in adults with overweight/obesity: the OASIS 4 RCT. 42nd Annual Meeting of The Obesity Society at ObesityWeek; San Antonio, TX; November 3–6, 2024. Available at: https://bit. ly/4kyvsl7. Accessed July 16, 2025.
- SP Marso et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311. doi:10.1056/nejmoa1603827
- In brief: GI effects of GLP-1 receptor agonists. Med Lett Drugs Ther 2023; 65:191.
- In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists. Med Lett Drugs Ther 2024; 66:201.
- RL Dubin et al. Glucagon-like peptide-1 receptor agonist-based agents and weight-loss composition: filling the gaps. Diabetes Obes Metab 2024; 26:5503. doi:10.1111/dom.15913
- American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2025. Diabetes Care 2025; 48(Suppl 1):S252. doi:10.2337/dc25-s012
- CX Cai et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol 2025; 143:304. doi:10.1001/jamaophthalmol.2024.6555
- KH Lewis et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring) 2019; 27:591. doi:10.1002/oby.22430
- Q Shi et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2024; 403:e21. doi:10.1016/s0140-6736(24)00351-9
- AS Kelly et al. Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evid 2022 April 30 (epub). doi:10.1056/evidoa2200014
- WT Garvey et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95:297. doi:10.3945/ajcn.111.024927
- A Siebenhofer et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev 2021; 1:CD007654. doi:10.1002/14651858.cd007654.pub5
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_ PGP_Tables.pdf.
- KM Gadde et al. Obesity: pathophysiology and management. J Am Coll Cardiol 2018; 71:69. doi:10.1016/j.jacc.2017.11.011
- Obalon Balloon System – another gastric balloon for weight loss. Med Lett Drugs Ther 2017; 59:102.
- ReShape and Orbera – two gastric balloon devices for weight loss. Med Lett Drugs Ther 2015; 57:122.
- T Muniraj et al. AGA clinical practice guidelines on intragastric balloons in the management of obesity. Gastroenterology 2021; 160:1799. doi:10.1053/j.gastro.2021.03.003
- AA Saber et al. Efficacy of first-time intragastric balloon in weight loss: a systematic review and meta-analysis of randomized controlled trials. Obes Surg 2017; 27:277. doi:10.1007/s11695-016-2296-8
- DL Chan et al. Outcomes with intra-gastric balloon therapy in BMI <35 non-morbid obesity: 10-year follow-up study of an RCT. Obes Surg 2021; 31:781. doi:10.1007/s11695-020- 04986-3
- EIN Presswire. Update: potential risks with liquid-filled intragastric balloons – letter to health care providers. April 27, 2020. Available at: https://bit.ly/4nsxMNh. Accessed July 16, 2025.
- JD Ard et al. Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study. Obesity (Silver Spring) 2025; 33:500. doi:10.1002/oby.24240
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
